Author Archives: Stacy Grieve, PhD

Aplidin-Dexamethasone Combo Improves Survival in Advanced Multiple Myeloma Patients, Phase 3 Trial Reports

Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial show. PharmaMar, Aplidin’s maker, presented these findings in an oral presentation at the recent 2018 American Society of Clinical Oncology (ASCO) Annual Meeting  in Chicago. …

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the…